Ipamorelin vs GHRP-6: Comparing GH Secretagogues for Research (UK 2026)

Ipamorelin and GHRP-6 (Growth Hormone-Releasing Peptide-6) are both ghrelin receptor (GHS-R1a) agonists that stimulate growth hormone release from the anterior pituitary. Despite this shared mechanism, they differ significantly in receptor selectivity, GH pulse profile, and co-secreted hormones — differences that substantially affect which compound is appropriate for different research questions.

Origins and Structure

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) developed in the 1980s from structure-activity relationship studies of enkephalin analogues. It was among the first synthetic GH secretagogues and played a central role in establishing that GH release could be stimulated independently of GHRH — ultimately contributing to the discovery of the ghrelin receptor (GHS-R1a).

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed later, specifically designed to be a highly selective GHS-R1a agonist. Its development was aimed at retaining GHRP-6’s GH-stimulating potency while eliminating the co-secretion of cortisol and prolactin that accompanied GHRP-6 use in research.

The Key Distinction: Receptor Selectivity

This is the most important difference between the two compounds and the primary factor in research compound selection.

GHRP-6 stimulates GH release but also significantly increases cortisol (via ACTH stimulation) and prolactin. In studies measuring these co-secreted hormones, GHRP-6-treated subjects show substantial elevations of both alongside GH increases. This broad receptor activity reflects GHRP-6’s interaction with receptors beyond GHS-R1a.

Ipamorelin was specifically engineered for GHS-R1a selectivity. Multiple published studies comparing the two compounds demonstrate that Ipamorelin produces equivalent or superior GH release with significantly less cortisol and prolactin co-secretion. In one landmark comparison study, Ipamorelin produced GH pulses comparable to GHRP-6 but caused only minor cortisol elevation and essentially no significant prolactin increase.

For research implications: if you want to study GH effects in isolation — without the confounding effects of elevated cortisol (which is catabolic, immunosuppressive, and affects body composition) and prolactin — Ipamorelin is the more appropriate tool. If your research question involves studying the broader ghrelin receptor system including its adrenocortical effects, GHRP-6’s less selective profile may be intentional.

GH Pulse Magnitude and Duration

At equivalent molar doses, GHRP-6 and Ipamorelin produce similar GH peak concentrations in most study designs. GHRP-6 produces a sharp, rapid GH peak that resolves within 60–90 minutes. Ipamorelin’s GH pulse is similarly acute — it is not extended compared to GHRP-6. Both are rapid-onset, short-duration GH secretagogues.

The quality of the GH pulse differs: Ipamorelin’s selectivity means the GH signal is less “contaminated” by the hormonal milieu changes (cortisol, prolactin) that accompany GHRP-6, potentially making downstream IGF-1 and metabolic readouts cleaner research endpoints.

Appetite Stimulation: Ghrelin Pathway Effects

GHRP-6 is a potent appetite stimulant. Ghrelin — the endogenous ligand for GHS-R1a — is known as the “hunger hormone,” and GHS-R1a agonism stimulates appetite through hypothalamic NPY/AgRP neuron activation. GHRP-6 reliably produces significant appetite increase in research subjects, which can be a confounding variable in body composition studies (where caloric intake is a critical controlled variable).

Ipamorelin produces substantially less appetite stimulation than GHRP-6 in animal models, despite activating the same receptor. This differential effect may reflect Ipamorelin’s partial agonism at the appetite-relevant GHS-R1a signalling pathways versus its fuller agonism at pituitary GH-releasing pathways. The reduced appetite effect makes Ipamorelin preferable for body composition research where appetite/caloric intake must be controlled.

Research Application Comparison

Use Ipamorelin for: clean GH axis research where cortisol and prolactin confounding must be minimised; body composition and anabolic research where appetite control is important; studies examining GH effects on IGF-1 without hypothalamic-adrenal axis confounding; longer-term protocols where sustained cortisol elevation would create welfare concerns in animal models.

Use GHRP-6 for: research specifically studying the broader ghrelin receptor system including its adrenocortical effects; appetite and food intake research (where GHRP-6’s strong orexigenic effect is the endpoint of interest); historical comparison purposes — as the reference secretagogue from the literature; dose-response characterisation of GHS-R1a across multiple receptor-mediated outcomes simultaneously.

Combination with GHRH Analogues

Both Ipamorelin and GHRP-6 are studied in combination with GHRH analogues (Sermorelin, CJC-1295), producing synergistic GH release through dual receptor pathway activation. Ipamorelin + CJC-1295 is the most commonly studied modern combination, producing robust GH secretion with lower off-target hormonal activity than GHRP-6-based combinations. GHRP-6 + GHRH combinations are extensively represented in earlier research literature.

Half-life and Administration

Both peptides have similar short half-lives — approximately 15–30 minutes — requiring frequent administration for sustained GH axis activation studies. This is characteristic of GH secretagogues generally; the alternative for extended activity is pairing with a long-acting GHRH analogue (CJC-1295 with DAC) rather than extending the secretagogue half-life.

Summary

Ipamorelin is the cleaner, more selective GH research tool — producing equivalent GH release with substantially less cortisol, prolactin, and appetite stimulation. GHRP-6 has the longer research history and broader receptor activity profile, making it appropriate when those broader effects are the subject of study. For most modern GH axis research designs where isolated GH effects are the goal, Ipamorelin is the preferred compound.